A Cross-Country Analysis of the Determinants of COVID-19 Fatalities
Toya et al., SSRN (Preprint)
Toya et al., A Cross-Country Analysis of the Determinants of COVID-19 Fatalities, SSRN (Preprint)
Country based analysis finding lower mortality with the use of HCQ.
Toya et al., 23 Apr 2021, preprint, 2 authors.
Abstract: re
v ie
we
d
9028
2021
April 2021
A Cross-Country Analysis of
the Determinants of Covid-19
Fatalities
Pr
ep
r
int
no
tp
ee
r
Hideki Toya, Mark Skidmore
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483
er
re
vie
we
d
Impressum:
Pr
ep
rin
tn
ot
pe
CESifo Working Papers
ISSN 2364-1428 (electronic version)
Publisher and distributor: Munich Society for the Promotion of Economic Research - CESifo
GmbH
The international platform of Ludwigs-Maximilians University’s Center for Economic Studies
and the ifo Institute
Poschingerstr. 5, 81679 Munich, Germany
Telephone +49 (0)89 2180-2740, Telefax +49 (0)89 2180-17845, email office@cesifo.de
Editor: Clemens Fuest
https://www.cesifo.org/en/wp
An electronic version of the paper may be
· from the SSRN website:
www.SSRN.com
· from the RePEc website:
www.RePEc.org
· from the CESifo website:
https://www.cesifo.org/en/wp
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483
iew
ed
CESifo Working Paper No. 9028
pe
er
re
v
A Cross-Country Analysis of the Determinants
of Covid-19 Fatalities
Abstract
Over the last year the world experienced the COVID-19 pandemic coupled with unprecedented
policy responses. In this paper we examine the determinants of COVID-19 infections and fatalities
in a cross-country analysis. We find that countries with greater income, less dense and greater
elderly populations, fewer hospital beds, and more freedom experienced greater fatalities, and that
travel restrictions and use of hydroxychloroquine reduced deaths. However, we find little evidence
that lockdowns reduced fatalities, and though use of PCR testing resulted in more recorded
infections, it was unassociated with fatalities.
JEL-Codes: O100, O200, Q540.
ot
Keywords: pandemic, Covid-19, fatalities.
Mark Skidmore
Michigan State University
67 Morrill Hall of Agriculture
USA – East Lansing, MI 48824-1039
mskidmor@msu.edu
ep
rin
tn
Hideki Toya
Faculty of Economics
Nagoya City University
Yamanohata-1, Mizuho-cho, Mizuho-ku
Japan – Nagoya, 467-8501
toya@econ.nagoya-cu.ac.jp
Pr
No organizations provided funding for this research.
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3832483
iew
ed
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit